Quick Answer
Kiniksa Pharmaceuticals International, plc reported Operating Income of $77.22 million for fiscal year 2025.
Kiniksa Pharmaceuticals International, plc Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | $77.22M | +269.3% |
| 2024 | -$45.62M | -81.0% |
| 2023 | -$25.20M | -357.8% |
| 2022 | $9.77M | +106.2% |
| 2021 | -$156.64M | +0.5% |
| 2020 | -$157.36M | +7.4% |
| 2019 | -$169.96M | -57.1% |
| 2018 | -$108.16M | -65.4% |
| 2017 | -$65.40M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $24.02M | +348.7% | +19.2% |
| June 30, 2025 | $20.16M | +17330.8% | +51.9% |
| March 31, 2025 | $13.27M | +180.2% | +237.4% |
| September 30, 2024 | -$9.66M | +11.6% | -8154.7% |
| June 30, 2024 | -$117.0K | +96.3% | +99.3% |
| March 31, 2024 | -$16.54M | -47.7% | -51.4% |
| September 30, 2023 | -$10.93M | -123.5% | -246.4% |
| June 30, 2023 | -$3.15M | +83.7% | +71.8% |
- Kiniksa Pharmaceuticals International, plc showed an increase of +269.3% in Operating Income compared to the prior fiscal year.
- Over the 2017–2025 period, Kiniksa Pharmaceuticals International, plc’s operating income has grown by 218.1% (from -$65.40 million to $77.22 million).
- The most recent figure is from Kiniksa Pharmaceuticals International, plc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: